BioSpace News Archive

Mednet, a provider of eClinical solutions for the global life sciences community and Bioforum, a global, data-focused contract research organization (CRO), announced a partnership designed to enhance the efficiency of clinical studies and increase their flexibility

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.

Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid analogs as new chemical entities, today announced Steve Orndorff Ph.D., Chief Operating Officer, will participate on a Biosynthesis panel at Cowen’s 2nd Annual Boston Cannabis Conference being held from November 12-13 2019 at the InterContinental hotel.

Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that it has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor

Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record second quarter revenues and adjusted operating income1 (“AOI”) for the three months ended September 30, 2019.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, announced that Jill Quigley, chief operating officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Wednesday, November 13th, 2019 at 9:30 a.m. ET in New York, NY..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming investor conferences.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Oncology Investor Conference on Wednesday, November 13, 2019 In New York and Stifel Healthcare Conference on Wednesday, November 20, 2019 in New York.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019